Theradiag SA
PAR:ALTER
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Theradiag SA
Theradiag SA
Total Liabilities & Equity
Theradiag SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theradiag SA
PAR:ALTER
|
Total Liabilities & Equity
€14.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Total Liabilities & Equity
€91.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Biomerieux SA
PAR:BIM
|
Total Liabilities & Equity
€5.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Carmat SA
PAR:ALCAR
|
Total Liabilities & Equity
€54.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Total Liabilities & Equity
€36.6m
|
CAGR 3-Years
84%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Total Liabilities & Equity
€279.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Theradiag SA
Glance View
Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.
See Also
What is Theradiag SA's Total Liabilities & Equity?
Total Liabilities & Equity
14.5m
EUR
Based on the financial report for Jun 30, 2023, Theradiag SA's Total Liabilities & Equity amounts to 14.5m EUR.
What is Theradiag SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
8%
Over the last year, the Total Liabilities & Equity growth was 1%. The average annual Total Liabilities & Equity growth rates for Theradiag SA have been 19% over the past three years , 8% over the past five years .
You don't have any saved screeners yet